Pyrazolone derivatives

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula

and pharmaceutically acceptable salts thereof, where substitutes R1-R4 are as defined in claim 1. Said compounds have 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) enzyme inhibiting activity.

EFFECT: compounds can be used in form of a pharmaceutical composition.

15 cl, 1 tbl, 94 ex

 

The text descriptions are given in facsimile form.

1. The compounds of formula
,
where R1means hydrogen, alkyl, cycloalkyl, aralkyl, halogenated, aryl, pyridinylmethyl or heterocyclyl; and provided that if R 1means hydrogen, then R3means of substituted;
R2means hydrogen, alkyl, aryl, aralkyl, benzothiazolyl or bicyclo(2.2.1)heptyl, where bicyclo(2.2.1)heptyl optionally contains from one to three substituents independently selected from alkyl;
or R1and R2together with the nitrogen atoms to which they are attached, form pyrazolidine, hexahydropyridine or (1,2)diazepam;
or R1and R4together form -(CH2)m-;
m is 4 or 5;
R3means cyclopropyl or substituted;
R4means hydrogen, alkyl, cycloalkyl, aryloxyalkyl, alkylcarboxylic, alkyloxyalkyl, aryl, aralkyl, halogenated or halogenosilanes;
where the term "aryl", alone or in combination, means a phenyl or naphthyl, optionally substituted by 1-3 substituents, independently selected from alkyl, halogen, alkoxy, triptoreline, nitro, trifloromethyl and alkyl-SO2;
the term "heterocyclyl"used in the definition of R1means pyridinyl;
and their pharmaceutically acceptable salts, provided that 1,2-dihydro-5-methyl-4-tricyclo(3.3.1.13,7)Dec-1-yl-3H-pyrazole-3-one are excluded.

2. Compounds according to claim 1, where
R1means hydrogen, alkyl, cycloalkyl, aralkyl, halogenated, aryl or pyridinyl; and provided that if R1means hydrogen, R3R2means hydrogen, alkyl, aryl, aralkyl or bicyclo(2.2.1)heptyl, where bicyclo(2.2.1)heptyl optionally contains from one to three substituents independently selected from alkyl;
or R1and R2together with the nitrogen atoms to which they are attached, form pyrazolidine, hexahydropyridine or (1,2)diazepam;
or R1and R4together form -(CH2)m-,
m is 4 or 5;
R4means hydrogen, alkyl, cycloalkyl, aryloxyalkyl, alkylcarboxylic, alkyloxyalkyl, aryl, aralkyl or halogenated.

3. Compounds according to claim 1, where R4means cyclopropyl, cyclobutyl, tert-butyl, fortunecity, florfenicol, chlorphenoxamine, dichlorodimethyl, isopropoxyphenyl, methyl, hydrogen or trifluoromethyl.

4. Compounds according to claim 1, where R4means cyclopropyl, cyclobutyl, tert-butyl or 4-forfinancial.

5. Compounds according to claim 1, where R3means of substituted, and R4means hydrogen, methyl or cyclopropyl.

6. Compounds according to claim 1, where R1means hydrogen, methyl, ethyl, isopropyl, benzyl, cyclopropylmethyl, phenyl, pyridinyl or forfinal.

7. Compounds according to claim 1, where R1means methyl or phenyl.

8. Compounds according to claim 1, where R2means hydrogen, methyl, ethyl, 1,7,7-trimethylbicyclo(2.2.1)hept-2-yl, phenyl or substituted phenyl, where the substituted phenyl oz is achet phenyl, containing from one to three substituents that are independently chosen from the group comprising fluorine, chlorine and trifluoromethyl.

9. Compounds according to claim 1, where R2means methyl, forfinal, chlorophenyl or triptoreline.

10. Compounds according to claim 1, which is selected from the group including
4,5-dicyclopropyl-1-methyl-2-phenyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2-forfinal)-1-methyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(4-forfinal)-1-methyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2,4-differenl)-1-methyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(3-forfinal)-1-methyl-1,2-dihydropyrazol-3-one,
2-(2-chlorophenyl)-4,5-dicyclopropyl-1-methyl-1,2-dihydropyrazol-3-one,
2-(3-chlorophenyl)-4,5-dicyclopropyl-1-methyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-1-methyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-1-methyl-2-(3-triptoreline)-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(4-fluoro-2-triptoreline)-1-methyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2-methoxyphenyl)-1-methyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-1-methyl-2-naphthalene-1-yl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-1-ethyl-2-(4-forfinal)-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-1-ethyl-2-(3-forfinal)-1,2-dihydropyrazol-3-one,
2-(2-chlorophenyl)-4,5-dicyclopropyl-1-ethyl-1,2-dihydropyrazol-3-one,
2-(3-chlorophenyl)-4,5-dicyclopropyl-1-ethyl-1,2-dihydropyrazol-3-the n
4,5-dicyclopropyl-1-ethyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
1-benzyl-4,5-dicyclopropyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-1-cyclopropylmethyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
2-benzyl-4,5-dicyclopropyl-1-methyl-1,2-dihydropyrazol-3-one,
2,3-dicyclopropyl-6,7,8,9-tetrahydro-5H-pyrazolo[1,2-a][1,2]diazepin-1-he,
5-cyclobutyl-4-cyclopropyl-1-methyl-2-phenyl-1,2-dihydropyrazol-3-one,
5-cyclobutyl-4-cyclopropyl-1-methyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
4-cyclopropyl-1-methyl-5-(1-methylcyclopropyl)-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
5-tert-butyl-4-cyclopropyl-1-methyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
4-cyclopropyl-5-(2,2-dimethylcyclopropane)-1-methyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
3-cyclopropyl-1-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-2-it,
4-cyclopropyl-5-(4-forfinancial)-1-methyl-2-phenyl-1,2-dihydropyrazol-3-one,
4-cyclopropyl-5-(4-forfinancial)-2-(4-forfinal)-1-methyl-1,2-dihydropyrazol-3-one,
N-{4-[4-cyclopropyl-1-(4-forfinal)-2-methyl-5-oxo-2,5-dihydro-1H-pyrazole-3-ylethoxy]phenyl}acetamide", she
N-{4-[4-cyclopropyl-1-(2-forfinal)-2-methyl-5-oxo-2,5-dihydro-1H-pyrazole-3-ylethoxy]phenyl}acetamide", she
4-cyclopropyl-5-(4-forfinancial)-2-(2-forfinal)-1-methyl-1,2-dihydropyrazol-3-one,
4-cyclopropyl-2-(4-forfinal)-5-[2-(4-forfinal)ethyl]-1-methyl-1,2-Digue is droperidol-3-one,
4-cyclopropyl-2-(2-forfinal)-5-[2-(4-forfinal)ethyl]-1-methyl-1,2-dihydropyrazol-3-one,
4-cyclopropyl-1-ethyl-5-(4-forfinancial)-2-(4-forfinal)-1,2-dihydropyrazol-3-one,
2-adamant-1-yl-3-methyl-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazole-1-he,
2-adamant-1-yl-3-methyl-5,6,7,8-tetrahydropyrazolo[1,2-a]pyridazin-1-he,
2-adamant-1-yl-3-methyl-6,7,8,9-tetrahydro-5H-pyrazolo[1,2-a][1,2]diazepin-1-he,
2-adamant-1-yl-3-cyclopropyl-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazole-1-he,
4-adamant-1-yl-1,2,5-trimethyl-1,2-dihydropyrazol-3-one,
4-adamant-1-yl-1-benzyl-2,5-dimethyl-1,2-dihydropyrazol-3-one,
4-adamant-1-yl-1-isopropyl-5-methyl-1,2-dihydropyrazol-3-one,
4-adamant-1-yl-5-methyl-2-phenyl-1,2-dihydropyrazol-3-one,
4-adamant-1-yl-1,5-dimethyl-2-phenyl-1,2-dihydropyrazol-3-one,
4-adamant-1-yl-2,5-dimethyl-1-phenyl-1,2-dihydropyrazol-3-one,
4-adamant-1-yl-5-methyl-1-phenyl-1,2-dihydropyrazol-3-one,
4-adamant-1-yl-1-phenyl-1,2-dihydropyrazol-3-one,
4-adamant-1-yl-2-methyl-1-phenyl-1,2-dihydropyrazol-3-one,
4-adamant-1-yl-5-methyl-1-pyridin-2-yl-1,2-dihydropyrazol-3-one,
4-adamant-1-yl-2,5-dimethyl-1-pyridin-2-yl-1,2-dihydropyrazol-3-one,
4-adamant-1-yl-1-(4-forfinal)-2,5-dimethyl-1,2-dihydropyrazol-3-one,
4-adamant-1-yl-2-ethyl-5-methyl-1-phenyl-1,2-dihydropyrazol-3-one,
3-adamant-1-yl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-2-it,
3-adamant-1-yl-1-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a]azepin-2-it,
3-adamant-1-yl-1-methyl-4,5,6,7-tetrahydropyrazolo what about[1,5-a]pyridine-2-it,
3-adamant-1-yl-1-ethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-2-it.

11. Compounds according to claim 1, which is selected from the group including
4,5-dicyclopropyl-2-(2-forfinal)-1-methyl-1,2-dihydropyrazol-3-one,
2-(2-chlorophenyl)-4,5-dicyclopropyl-1-methyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-1-methyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
5-cyclobutyl-4-cyclopropyl-1-methyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
4-cyclopropyl-1-methyl-5-(1-methylcyclopropyl)-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
5-tert-butyl-4-cyclopropyl-1-methyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
4-cyclopropyl-5-(2,2-dimethylcyclopropane)-1-methyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
4-cyclopropyl-5-(4-forfinancial)-2-(2-forfinal)-1-methyl-1,2-dihydropyrazol-3-one,
2-adamant-1-yl-3-methyl-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazole-1-he,
4-adamant-1-yl-2,5-dimethyl-1-phenyl-1,2-dihydropyrazol-3-one and
3-adamant-1-yl-1-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-2-it.

12. Compounds according to claim 1, which is selected from the group including
4,5-dicyclopropyl-2-(2,3-dichlorophenyl)-1-methyl-1,2-dihydropyrazol-3-one,
1-benzyl-4,5-dicyclopropyl-2-(2,4-differenl)-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2,4-differenl)-1-(2-terbisil)-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2,4-differenl)-1-(4-terbisil)-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(3-fluoro-2-triptime fenil)-1-methyl-1,2-dihydropyrazol-3-one,
1-benzyl-4,5-dicyclopropyl-2-(2,5-differenl)-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2,5-differenl)-1-methyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-1-methyl-2-(2-trifloromethyl)-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-1-(2,4-diferensial)-2-(2,5-differenl)-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2,4-differenl)-1-(3,3,3-cryptochromes)-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2,4-differenl)-1-pyridin-2-ylmethyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-1-methyl-2-ortho-tolyl-1,2-dihydropyrazol-3-one,
2-benzothiazol-2-yl-4,5-dicyclopropyl-1-methyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2,3-dimetilfenil)-1-methyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2-ethylphenyl)-1-methyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2,5-dichlorophenyl)-1-methyl-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2-fluoro-3-methyl-6-triptoreline)-1-methyl-1,2-dihydropyrazol-3-one,
4-cyclopropyl-1-methyl-5-trifluoromethyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
4-cyclopropyl-5-(2,2-diversicolor)-1-methyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
4-cyclopropyl-5-(3,3-diversilobum)-1-methyl-2-(2-triptoreline)-1,2-dihydropyrazol-3-one,
4,5-dicyclopropyl-2-(2,4-differenl)-1-(2,2,2-triptorelin)-1,2-dihydropyrazol-3-one and
4,5-dicyclopropyl-2-(2,2-dimethylpropyl)-1-methyl-1,2-dihydropyrazol-3-one.

13. Compounds according to any one of claims 1 to 12, with ing Bermuda activity against the enzyme 11β-hydroxysteroiddehydrogenase 1 (11β-HSD1).

14. Compounds according to any one of claims 1 to 12 for medicinal products intended for the prevention and treatment of diseases that are caused by disorders associated with enzyme 11β-hydroxysteroiddehydrogenase 1.

15. Pharmaceutical composition having inhibitory activity against the enzyme 11β-hydroxysteroiddehydrogenase 1 (11β-HSD1), which includes the compound according to any one of claims 1 to 12 and a therapeutically inert carrier.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new imidazopyrazines of formula where Q1 and R1 have the values specified in the patent claim, and to their pharmaceutically acceptable salts showing IGF-1R enzyme inhibiting activity and applicable for treatment and/or prevention of various diseases and conditions which are sensitive to tyrosine kinase inhibition.

EFFECT: preparation of the compounds showing IGF-1R enzyme inhibiting activity.

27 cl, 294 ex

Chemical compounds // 2405780

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new compounds of formula (I): , in which: R1 and R2 are independently specified from hydrogen, C1-6alkyl, C1-6alkoxy and cyclopropyl; X1, X2 and X3 independently represent =N- or =CR10; R3 and R10 are independently specified from hydrogen, halogen, nitro, cyano, amino, carboxy, carbamoyl, C1-6alkyl, N-(C1-6alkyl)amino, N,N(C1-6alkyl)2amino, C1-6alkanoylamino, C1-6alkoxycarbonyl; R4 represents hydrogen; R5 and R6 are independently specified from hydrogen, hydroxy and C1-6alkyl where R5 and R6 independently can be optionally substituted in carbon atom with one or more R16 where R16 represents hydroxy; A represents a single link or C1-2alkylene; where specified C1-2alkylene can be optionally substituted with one or more R18; the ring C represents a saturated, partially saturated or unsaturated mono- or bicyclic ring containing 5 or 6 atoms in which at least one atom can be specified from nitrogen, sulphur or oxygen which can be linked with carbon or nitrogen atom where the -CH2- group can be optionally substituted with -C(O)- and ring sulphur atom can be optionally oxidised to produce S-oxide; R7 is specified from halogen and C1-6alkyl where R7 can be optionally substituted in carbon atom with halogen; n is equal to 0.1 or 2; where R7 values can be equal or different; and R18 is independently specified from halogen and hydroxy; or its pharmaceutically acceptable salt. Also the invention refers to their pharmaceutical compositions and methods for preparation and application thereof for cancer treatment.

EFFECT: preparation of new compounds which can find application for cancer treatment.

23 cl, 96 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method for synthesis of N-(5-[3-(thiophene-2-carbonyl)-pyrazole[1,5-a]pyrimidin-7-yl]-2-fluoro-phenyl}-N-methyl-acetamide in polymorphic modification B, in which (5-amino-1H-pyrazol-4-yl)-thiophen-2-yl-methanone reacts with N-[5-(3-dimethylamino-acryloyl)-2-fluoro-phenyl]-N-methyl-acetamide in a solvent selected from a group comprising acetic acid, propionic acid and methanoic acid at 50°C until boiling point of the mixture is reached. (C1-C4)-alcohol is then added to the obtained mixture at temperature of 40°C-80°C, after which the obtained mixture is kept for at least 30 minutes a temperature of 30°C- 55°C for initiating crystallisation. The crystalline product is then separated.

EFFECT: method of obtaining a compound in polymorphic modification B, which can be used in medicine in treating and preventing anxiety, epilepsy, sleep disorders and insomnia.

8 cl, 3 dwg, 1 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method for synthesis of derivatives in the family of pyrrole[3,4-c]carbazole, and specifically to a method for synthesis of novel 2-R1-6-R2-5-aryl-pyrrole[3,4-c]carbazole-1,3(2H,6H)-diones of formula I: , where R1=:C1-C6 alkylphenyl, C1-C6 dialkylphenyl, C1-C6 dialkylphenyl dioxy C1-C6 alkyl; R2=C1-C6 alkyl; Ar=phenyl, C1-C6 alkyl phenyl, oxyalkylphenyl, halophenyl, having potential anticancer activity. The method involves reacting 1-R2-indolin-2-ones of general formula II with oxalyl chloride and 4-aryl-3-butenoic acid of general formula III, reacting the formed 3-(2-chloro-1-R2-1H-indol-3-yl)-4-[(E)-2-arylethenyl]furan-2,5-diones of general formula IV with R1-amines of general formula R1-NH2 V, and then photocyclisation of the formed 1-alkyl-3-(2-chloro-1-R2 -1H-indol-3-yl)-4-[(E)-2-arylethenyl]-1H-pyrrole-2,5-diones of general formula VI, where R1, R2 and Ar assume values listed above.

EFFECT: method for synthesis of novel derivatives having potential anticancer activity.

FIELD: chemistry.

SUBSTANCE: invention describes a novel compound - a sodium salt of 2-ethylthio-6-nitro-1,2,4-triazole[5,1-c]-1,2,4-triazin-7-one dihydrate of formula (1)

.

EFFECT: higher antiviral activity which can be used in medicine, stockbreeding and poultry farming.

2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel compounds, which inhibit HIV replication, of formula (I) , its pharmaceutically acceptable additive salt; or stereochemically isomer form, where -a1=a2-a3=a4-represents bivalent radical of formula -CH=CH-CH=CH- (a-1); -b1=b2-b3=b4 -represents bivalent radical of formula -CH=CH-CH=CH- (b-1); n represents 0; m represents 1, 2; -A-B- represents bivalent radical of formula -CR5=N- (c-1); -N=N- (c-2); -CH2-CH2- (c-3); -CS-NH- (c-4); -CH=CH- (c-6); R1 represents hydrogen; R2a represents cyano; R3 represents cyano-substituted C1-6alkyl; cyano-substituted C2-6lkenyl; each of R4 independently represents halogen or C1-6alkyl; Q represents hydrogen or C1-6alkyl; R5 represents hydrogen, C1-6alkyl, aryl, pyridyl, thienyl, furanyl, amino, mono- or di(C1-4alkyl)amino, where aryl represents phenyl. Invention also relates to pharmaceutical composition, application and method of obtaining compounds.

EFFECT: obtaining novel compounds, which inhibit HIV replication.

5 cl, 25 dwg, 7 tbl, 16 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are described novel acylsulfonamide peri-substituted condensed bicyclic compounds of general formula (I), values of radicals are given in invention formula. Also described is pharmaceutical composition based on formula (I) compound.

EFFECT: compounds can be used for inhibition of prostaglandin E2 binding with receptor EP3.

30 cl, 371 ex, 4 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel pyrazole-pyrimidine derivatives having metabotropic glutamate receptor (mGluR2) antagonist properties and having formula (1): , where A is selected from a group consisting of: Ra is H, halogen or C1-6-alkyl; R1 is II, halogen, C1-6-alkoxy, C1-6-alkyl, C1-6-haloalkyl, C1-6-haloalkoxy; R2 is a halogen, C1-6-haloalkyl; R3 is NRbRc, where Rb and Rc are independently selected from a group consisting of H and C1-6-alkyl which is possibly substituted with one or more substitutes selected from a group consisting of hydroxy and -NRb'Rc', where Rb' and Rc' are independently selected from a group consisting of H and C1-6-alkyl; or Rb and Rc together with the nitrogen atom to which they are bonded form a possibly substituted heterocyclic group containing 5-6 ring atoms, possibly containing an additional N heteroatom, where the substitutes are selected from a group consisting of hydroxy and C1-6-alkyl, R4 is C1-6-haloalkyl or C3-4-cycloalkyl; as well as to pharmaceutically acceptable salts thereof. The invention also relates to a pharmaceutical composition and use of the compounds in preparing a medicinal agent for treating or preventing diseases and conditions in which mGluR2 activation plays a role.

EFFECT: improved properties of compounds.

10 cl, 2 dwg, 1 tbl, 129 ex

FIELD: chemistry.

SUBSTANCE: invention describes a sodium salt of 2-n-propylthio-6-nitro-1,2,4-triazole[5,1-c]-1,2,4-triazin-7(4H)-one dihydrate and a sodium salt of 2-n-butylthio-6-nitro-1,2,4-triazole[5,1-c]-1,2,4-triazin-7(4H)-one dihydrate having antiviral activity on herpes simplex virus HSV-1.

EFFECT: higher antiviral effect of the compounds.

1 cl, 1 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel 1-substituted 3-(2-chloro-1H-indol-3-yl)-4-phenyl-1H-pyrrole-2,5-diones of formula 1: , where R1 denotes H, C1-C6alkyl; R2 denotes compounds which, under the effect of visible light, form fluorescent 2,8-substituted benzo[a]pyrrolo[3,4-c]carbazole-1,3-(2H,8H)diones of formula II: , where R1 and R2 are as described above.

EFFECT: more effective use of the compounds.

10 cl, 2 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: compound under the invention is represented by formula (I) or its pharmaceutically acceptable salt where R1 and R2 represent H or optionally substituted alkyl where substitutes are specified from -N(CH3)2, -OH, -OCH3; B represents N; Z represents N; each of W, X and Y independently represents C-H, C-J; Ar represents an optionally substituted phenyl ring where substitutes are specified from halogen, -NH-CH3; each J independently represents NR1R2; and n is equal to 0; provided the compound is not 4-[2-(5-chloro-2-fluorophenyl)pteridine-4-ylamino]nicotinamide. The compounds of formula (I) can find application in treating HCV related conditions.

EFFECT: preparation of the new compounds for making a drug for treating HCV infection.

15 cl, 2 tbl, 9 ex

Chemical compounds // 2405780

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new compounds of formula (I): , in which: R1 and R2 are independently specified from hydrogen, C1-6alkyl, C1-6alkoxy and cyclopropyl; X1, X2 and X3 independently represent =N- or =CR10; R3 and R10 are independently specified from hydrogen, halogen, nitro, cyano, amino, carboxy, carbamoyl, C1-6alkyl, N-(C1-6alkyl)amino, N,N(C1-6alkyl)2amino, C1-6alkanoylamino, C1-6alkoxycarbonyl; R4 represents hydrogen; R5 and R6 are independently specified from hydrogen, hydroxy and C1-6alkyl where R5 and R6 independently can be optionally substituted in carbon atom with one or more R16 where R16 represents hydroxy; A represents a single link or C1-2alkylene; where specified C1-2alkylene can be optionally substituted with one or more R18; the ring C represents a saturated, partially saturated or unsaturated mono- or bicyclic ring containing 5 or 6 atoms in which at least one atom can be specified from nitrogen, sulphur or oxygen which can be linked with carbon or nitrogen atom where the -CH2- group can be optionally substituted with -C(O)- and ring sulphur atom can be optionally oxidised to produce S-oxide; R7 is specified from halogen and C1-6alkyl where R7 can be optionally substituted in carbon atom with halogen; n is equal to 0.1 or 2; where R7 values can be equal or different; and R18 is independently specified from halogen and hydroxy; or its pharmaceutically acceptable salt. Also the invention refers to their pharmaceutical compositions and methods for preparation and application thereof for cancer treatment.

EFFECT: preparation of new compounds which can find application for cancer treatment.

23 cl, 96 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of general formula where: R1 denotes -OR1', -SR1", 6-member heterocycloalkyl with one O atom and possibly one N atom, phenyl or 5-member heteroaryl with two N atoms, 6-member heteraryl with one N atom; R1'/R1" denote C1-6-alkyl, C1-6-alkyl substituted with a halogen, -(CH2)x-C3-6cycloalkyl or -(CH2)x-phenyl; R2 denotes S(O)2-C1-6-alkyl, -S(O)2NH-C1-6-alkyl, CN; denotes the group: , and where one extra N atom of the nucleus of an aromatic or partially aromatic bicyclic amine may be present in form of its oxide ; R3 - R10 denotes H, halogen, C1-6-alkyl, C3-6cycloalkyl, 4-6-member heterocycloalkyl with one N or O atom, 6-member heterocycloalkyl with two O atoms or two N atoms, 6-8-member heterocycloalkyl containing on N atom or one O or S atom, 5-member heteroaryl with two or three N atoms, 5-member heteroaryl with one S atom, in which one carbon atom may be also substituted with N or O, 6-member heteroaryl with one or two N atoms, C1-6-alkoxy, CN, NO2, NH2, phenyl, -C(O)-5-member cyclic amide, S-C1-6-alkyl, -S(O)2-C1-6-alkyl, C1-6-alkyl substituted with halogen;C1-6-alkoxy substituted with halogen, C1-6-alkyl substituted with OH, -O-(CH2)y-C1-6-alkoxy, -O(CH2)yC(O)N(C1-6-alkyl)2, -C(O)-C1-6-alkyl, -O-(CH2)x-phenyl, -O-(CH2)x-C3-6cycloalkyl, -O-(CH2)x-6-member heterocycloalkyl with one O atom, -C(O)O-C1-6-alkyl, -C(O)-NH-C1-6-alkyl, -C(O)-N(C1-6-alkyl)2, 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl or 3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl; R' and R'" in group (e) together with -(CH2)2- with which it is bonded can form a 6-member ring; R, R', R" and R"' independently denote H, C1-6-alkyl; and where all groups - phenyl, cycloalkyl, cyclic amine, heterocycloalkyl or 5- or 6-member heteroaryl, as defined for R1, R1', R1" and R3 - R10, can be unsubstituted or substituted with one or more substitutes selected from OH, =O, halogen, C1-6-alkyl, phenyl, C1-6-alkyl substituted with halogen, or C1-6-alkoxy; n, m o, p, q, r, s and t = 1 , 2; x =0, 1 or 2; y = 1 , 2; and their pharmaceutically acceptable acid addition salts.

EFFECT: compounds have glycine transporter 1 inhibiting activity, which enables their use in a pharmaceutical composition.

20 cl, 2 tbl, 12 dwg, 382 ex

FIELD: medicine.

SUBSTANCE: invention refers to new derivatives of dihydro-pyrroloquinoline of formula I where values of R1, R2, R3a and R3c radicals are specified in cl. 1 of the patent claim. Also the invention refers to a method for making the compound of formula I, to its application, a composite product based on the compound of formula I and a general antimicrobial agent and a pharmaceutical composition based on the compound of formula I.

EFFECT: there are prepared new derivatives of dihydro-pyrroloquinoline exhibiting antibacterial activity.

26 cl, 4 dwg, 11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel substituted 8-sulphonyl-2,3,4,5-tetrahydro-1H-γ-carbolines of general formula 1 or pharmaceutically acceptable salts thereof, which are ligands with a wider range of simultaneous activity towards alpha adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors, sigma receptors, norepiniphrine receptors and serotonin receptors. In compounds of general formula 1 R1 is an amino group substitute selected from hydrogen; C1-C3alkyl optionally substituted with phenyl; C1-C4alkyloxycarbonyl; R2 is a cyclic system substitute selected from hydrogen, C1-C3alkyl optionally substituted with phenyl, pyridin-(3- or 4-yl), (6-methylpyridin-3-yl); C1-C3alkenyl substituted with phenyl; or optionally substituted phenylsulphonyl; R3 is an optionally halogen-substituted phenyl, six member aromatic azaheterocycle, mono- or di-C1-C3alkylamino group, phenylamino group which is optionally substituted with halogen atoms on the phenyl ring, or a substituted six member azaheterocycle containing an additional nitrogen atom, substituted with C1-C3alkyl.

EFFECT: compounds can be used in treating and preventing diseases and pathological conditions of the central nervous system, such as anxiety disorders, cognitive disorders, neurodegenerative diseases and depression.

18 cl, 2 dwg, 6 tbl, 23 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to compounds of formula IB , where radicals R1-R5 have values, given in invention formula. In range of claimed invention also described are pharmaceutical compositions, which include compounds of IB formula, and methods of application of such compounds and compositions for treatment of different malfunctions, mainly selected from immune response reactions.

EFFECT: compounds by claimed invention have inhibiting action with respect to proteinkinases and, in particular with respect to JAK-3, ROCK or Aurora kinases.

55 cl, 6 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of general formula: I, where R1 is selected from hydrogen or methoxy; R2 is selected from a group consisting of hydroxy, lower alkoxy, provided that R2 does not denoe methoxy when R1 denotes methoxy, lower alkoxy, mono- or di-substituted with a hydroxy group, benzyloxy, amino, alkylamino, dialkylamino, cyano group, unsubstituted phenyl or tetrazolyl, -O-(CH2)m-C(O)-NR8R9, where m equals 1 or 2, and where R8 and R9 are independently selected from hydrogen, lower alkyl or tetrazolyl, or R8 and R9 together with the nitrogen atom with which they are bonded form morpholinyl or piperazinyl, -O-(CH2)n-COOR10, where n equals 1 or 2 and R10 denotes hydrogen or lower alkyl, -O-(CH2)p-NH-C(O)-OR11, where p equals 1 or 2,and where R11 denotes lower alkyl, -O-SO2-R12, where R12 denotes lower alkyl, -NR13R14, where R13 denotes hydrogen or lower alkyl, and R14 denotes lower alkyl or benzyl, and -NH-CO-(CH2)q-R15, where q equals 1 or 2, and where R5 denotes tetrazolyl; R3 is selected from a group consisting of hydrogen, hydroxy, lower alkoxy, lower alkoxy which is mono- or di-substituted with a hydroxy group, alkoxy or unsubstituted phenyl, and -O-(CH2)m-C(O)-NR8R9, where m equals 1 or 2, and where R8 and R9 are independently selected from hydrogen or lower alkyl, or R8 and R9 together with the nitrogen atom with which they are bonded form morpholinyl or piperazinyl, which can be substituted with lower alkyl; R4 is or , where R5 is selected from lower alkyl; or R5 can also denote hydrogen when selected from a group consisting of -(CH2)m-C(O)-NR8R9, -O-(CH2)p-NH-C(O)-OR11, -O-SO2-R12, -NR13R14, -NH-CO-(CH2)q-R15 and lower alkoxy which is mono- or di-substituted with a group selected from hydroxy, benzyloxy, amino or cyano; R6 is selected from a group consisting of hydrogen and lower alkyl; R7 is selected from a group consisting of lower alkyl and lower halogenalkyl; and to pharmaceutically acceptable salts of said compounds. The invention also pertains to a pharmaceutical composition.

EFFECT: obtaining novel biologically active compounds having DPP-IV enzyme inhibiting activity.

22 cl, 50 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives of general formula , where R is an optional ortho- or meta-substitute selected from halogen and (C1-4)alkyloxy; R1 is halogen or CF3; R2 is H, (C1-4)alkyloxy or halogen; R3 is H or (CH2)n-NR5R6; R4 is H or (C1-6)alkyl, optionally substituted COOR7 or NR8R9; R5 and R6 independently denote H, (C3-8)cycloalkyl, quinuclidin-3-yl, (C2-6)alkenyl or (C1-6)alkyl, optionally substituted mono-substituted with CF3, (C3-8)cycloalkyl, (C6)aryl, a 5- or 6-member heteroaryl group, OH, (C1-6)alkyloxy, (C6-10)aryloxy, CONR11R12, NR13R14 or NR13SO2(C1-4)alkyl; or R5 and R6 together with a nitrogen atom to which they are bonded form a 4-8-member saturated heterocyclic ring which also contains 1 heteroatom selected from O, SO2 and NR15, where the ring is optionally mono-substituted or di-substituted with oxo, (C1-4)alkyl, (C3-8)cycloalkyl, NR16R17 or CONR18R19; R7 is H or (C1-4)alkyl; R8 and R9 independently denote H, (C1-4)alkyl (optionally substituted di(C1-4)alkylamino) or (C3-8)cycloalkyl; or R8 and R9 together with a nitrogen atom with which they are bonded form a 4-8-member saturated heterocyclic ring which also contains one heteroatom which is O; R11 and R12 independently denote H or (C1-4)alkyl; R13 and R14 independently denote H or (C1-4)alkyl; R15 is H, (C1-4)alkyl (optionally mono-substituted OH, (C1-4)alkyloxy or di(C1-4)alkylamino), phenyl, pyridyl or COR20; R16 and R17 denote (C1-4)alkyl; or R16 and R17 together with a nitrogen atom with which they are bonded from a 4-8-member saturated heterocyclic ring; R18 and R19 denote H; R20 is (C1-4)alkyl, (C3-8)cycloalkyl or furyl; and n equals 0 or 1; or its pharmaceutically acceptable salt. The invention also relates to use of formula I compounds to prepare a medicinal agent and to a pharmaceutical composition based on formula I compound.

EFFECT: novel derivatives have catepsin S and K inhibitory activity.

9 cl, 20 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound which exhibits inhibitory effect on the FAAH enzyme having formula I , where n denotes an integer from 1 to 6; A denotes a group X; where when n equals an integer from 2 to 6, groups A are identical or different; X denotes C1-2-alkylene; R1 denotes a hydrogen atom; R2 denotes a hydrogen atom or a group selected from the following groups: phenyl, phenyloxy; R3 denotes either 2,2,2-trifluoroethyl or phenyl, if necessary substituted with one or more halogen atoms or C1-3-alkyl, C1-3-alkoxy, trifluoromethyl; provided that: the formula 1 compound is not 2,2,2-trifluoroethyl benzylcarbamate, when R3 denotes 2,2,2-trifluoroethyl and group -[A]n- denotes a -CH2- group, when R3 denotes phenyl, if necessary substituted, and group -[A]n-denotes a -CH2-, -CH2CH2-,-CH2CH2CH2- group, then R2 is not a hydrogen atom and is in form of a base, an addition salt with a pharmaceutically acceptable acid, as well as to a method for synthesis of the formula I compound and a pharmaceutical composition having inhibitory effect on FAAH, containing at least one formula I compound.

EFFECT: improved method.

5 cl, 6 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: present invention pertains to novel pyrrolo[3,2-b]pyridine derivatives of formula I , where values of radicals R1-R5 are given in the description. The invention also covers pharmaceutically acceptable salts of these compounds, methods of producing these compounds and pharmaceutical compositions containing these compounds. Pyrrolo[3,2-b]pyridine derivatives and their pharmaceutically acceptable salts can provide proton pump reversible inhibitory effect.

EFFECT: obtaining novel pharmaceutically acceptable salts which can provide proton pump reversible inhibitory effect.

5 cl, 2 tbl, 289 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new compounds of formula (I) and to its pharmaceutically acceptable additive salts, optionally in the form of stereochemical isomer and exhibiting anti-HIV antiviral activity, particularly having HIV inhibitor properties and applied as a drug. In formula , -a1=a2-a3=a4- represents a bivalent radical of formula -CH=CH-CH=CH-(a-1); -b1=b2-b3-b4 - represents a bivalent radical of formula -CH=CH-CH=CH- (b-1); n is equal to 0, 1, 2, 3, 4; m is equal to 0, 1, 2; each R1 independently represents hydrogen; each R2 represents hydrogen; R2a represents cyano; X1 represents -NR1-; R3 represents C1-6alkyl, substituted cyano; C2-6alkrnyl, substituted cyano; R4 represents halogen; C1-6alkyl; R5 represents 5 or 6-member completely unsaturated cyclic system where one, two or three members of the cycle represent heteroatoms, each independently specified from the group consisting of nitrogen, oxygen and sulphur and where the rest members of the cycle represent carbon atoms; and where 6-member cyclic system can be optionally annelated with a benzene cycle; and where any carbon atom in the cycle can be independently optionally substituted with a substitute specified from C1-6alkyl, amino, mono- and diC1-4alkylamino, aminocarbonyl, mono-and diC1-4alkylcarbonylamino, phenyl and Het; where Het represents pyridyl, thienyl, furanyl; Q represents hydrogen The invention also concerns a pharmaceutical composition.

EFFECT: preparation of the new anti-HIV antiviral compounds.

4 cl, 2 tbl, 22 ex

Up!